You just read:

Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients

News provided by

Eli Lilly and Company

May 19, 2011, 08:11 ET